The number of physician-scientists and translational researchers working in lung cancer has not kept pace with the overall growth of the medical research community or with the growth in our basic knowledge base, resulting in an increasing number of unrealized basic and translational research opportunities. Yale is uniquely suited to helping rebuild this base with our strong commitment to basic and translational research. The Career Development Program (CDP) in the Yale SPORE in Lung Cancer (YSILC) has been designed to contribute substantively to ongoing efforts and new initiatives attempting to address this problem. Our translational research office at Yale (led by Dr. Herbst) has been committed to providing early seed funding and translational support to young investigators early in their research careers. The goal of the CDP is to educate a new generation of investigators committed to translational research in lung cancer. The CDP has substantial institutional commitment, both in terms of funding and infrastructure. Potential CDP candidates include promising junior faculty who are interested in establishing their career in translational lung cancer research or established investigators whose previous research has been in other areas. Junior faculty awardees will be paired with more established investigators in lung cancer research with a documented record of successful mentoring. In this way, the YSILC will stimulate the development of the next generation of physician scientists and translational researchers, addressing the most challenging issues in lung cancer research.

Public Health Relevance

PROGRAM NARRATIVE The Yale SPORE in Lung Cancer?s Career Development Program is a key program to foster the development of the next generation of physician-scientists in the area of human thoracic malignancies to faciliate diagnosis, prevention, and therapy of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA196530-02
Application #
9149461
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Program Officer
Ujhazy, Peter
Project Start
Project End
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
2
Fiscal Year
2016
Total Cost
$47,249
Indirect Cost
Name
Yale University
Department
Microbiology/Immun/Virology
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Burslem, George M; Smith, Blake E; Lai, Ashton C et al. (2018) The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. Cell Chem Biol 25:67-77.e3
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Choe, Junho; Lin, Shuibin; Zhang, Wencai et al. (2018) mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature 561:556-560
Bade, Brett C; Hyer, J Madison; Bevill, Benjamin T et al. (2018) A Patient-Centered Activity Regimen Improves Participation in Physical Activity Interventions in Advanced-Stage Lung Cancer. Integr Cancer Ther 17:921-927
Tentori, Augusto M; Nagarajan, Maxwell B; Kim, Jae Jung et al. (2018) Quantitative and multiplex microRNA assays from unprocessed cells in isolated nanoliter well arrays. Lab Chip 18:2410-2424
Fan, Pang-Dian; Narzisi, Giuseppe; Jayaprakash, Anitha D et al. (2018) YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci U S A 115:E6030-E6038
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Bondeson, Daniel P; Smith, Blake E; Burslem, George M et al. (2018) Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Cell Chem Biol 25:78-87.e5
O'Malley, Stephanie S; Zweben, Allen; Fucito, Lisa M et al. (2018) Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA Psychiatry 75:129-138

Showing the most recent 10 out of 74 publications